ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 580

Tenascin-C, a TLR 4 Endogenous Ligand Levels Are Increased in Ankylosing Spondylitis

Latika Gupta, Shruti Bhattacharya and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: AS, biomarker, inflammation and innate immunity, Toll Like receptors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Monocytes of patients with Ankylosing Spondylitis (AS) over-express Toll-like receptor (TLR) 4 on their monocytes. Tenascin-C (TNC) is an extracellular-matrix-glycoprotein and acts as an endogenous TLR4 ligand. Thus we studied the serum and synovial fluid levels of TNC in adults with AS.

Methods:

TNC was measured in serum of 36 AS patients (ASAS 2009 criteria) and 10 healthy controls by ELISA. 22 patients were followed-up after 3 months of standard of care treatment. Five paired serum-synovial fluid samples were also analyzed. Disease activity was assessed by BASDAI, ASDAS, tender and swollen joint count; enthesitis score, ESR and CRP. All values are in median (IQR).

Results:

Median age was 30 (20-35) years and disease duration 5.5(1.3-10) years. 31 were male and 5 female. 25 cases had peripheral arthritis (69.5%). Median BASDAI was 5.3(3.3-6.7). HLA B27 was positive in 34 (94.5%) cases.

Median serum Tenascin C levels were higher in AS [554.6ng/ml] as compared to healthy controls [32.88 ng/ml, p<0.00001]. Serum TNC levels correlated with ASDAS ESR [r=0.367, p=0.028] and ESR [r=0.39, p=0.035]; but not with other disease activity measures. In patients with disease duration less than 5 years (early disease) serum levels had better correlation with ESR [r=0.59, p=0.009] and CRP [r=0.479, p=0.044]. On ROC analysis for active (PhGA≥6) vs. inactive (PhGA≤4) disease, TNC (AUC=0.60) performed as well as CRP (AUC=0.65) and ESR (AUC=0.73). The synovial fluid levels [11.61(5.99-176.9) ng/ml] were lower than in the serum [627.4 (488.5-779.1) ng/ml, p=0.008].

TNC levels fell with treatment [630.8 ng/ml to 376.4 ng/ml p=0.0006] in treatment responders (n=11) but not in non- responders (n=11) [562.3 to 445.6,p=0.33].

Conclusion:

Serum TNC levels are significantly raised in AS and can serve as marker of inflammation in early disease. Treatment reduces the TNC levels, probably due to control of disease activity.


Disclosure: L. Gupta, none, 2; S. Bhattacharya, None; A. Aggarwal, None.

To cite this abstract in AMA style:

Gupta L, Bhattacharya S, Aggarwal A. Tenascin-C, a TLR 4 Endogenous Ligand Levels Are Increased in Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tenascin-c-a-tlr-4-endogenous-ligand-levels-are-increased-in-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tenascin-c-a-tlr-4-endogenous-ligand-levels-are-increased-in-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology